Conatus Pharmaceuticals Soars 40% Ahead Of Emricasan Results

Shares of Conatus Pharmaceuticals Inc CNAT soared approximately 40 percent on Monday following an upcoming announcement on its ACLF Emricasan trial.

According to the company’s press release, it will report top-line results from three clinical trials in subjects with varying degrees of organ impairment.

The company will announce Phase 2 trial results in patients with acute-on-chronic liver failure (ACLF), a Phase 1 trial in patients with mild, moderate and severe hepatic impairment and a Phase 1 trial in patients with severe renal impairment.

The announcement will be made after the market close on Thursday, January 8.

Conatus Pharmaceuticals recently traded at $10.31, up 27.8 percent.